Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database
2024

Real-World Prevalence and Treatment of HER2-Mutant Lung Cancer

Sample size: 164 publication 10 minutes Evidence: moderate

Author Information

Author(s): Waliany Sarah, Nagasaka Misako, Park Leah, Lam Clara, Jiang Zoe, Lin Feng, Neal Joel W.

Hypothesis

What are the treatment patterns and outcomes for patients with HER2-mutant metastatic non-small cell lung cancer in a real-world setting?

Conclusion

The study found that most patients with HER2-mutant metastatic non-small cell lung cancer received chemotherapy or immune checkpoint inhibitors, with a median overall survival of 13.2 months.

Supporting Evidence

  • Among 9206 patients with mNSCLC, 164 (1.78%) had HER2 mutations.
  • 80.5% of patients received at least one line of treatment.
  • Platinum-based chemotherapy was the most common first-line treatment at 45.5%.

Takeaway

Doctors looked at how many people with a specific type of lung cancer got treated and how well they did. They found that most people got chemotherapy and lived for about a year.

Methodology

This was a retrospective observational study using a US nationwide de-identified NSCLC clinico-genomic database.

Limitations

The study was descriptive with small sample sizes in treatment categories and limited follow-up time.

Participant Demographics

{"mean_age":67.3,"gender_distribution":{"female":56.7,"male":43.3},"ethnicity_distribution":{"White":63.4,"Black_or_African_American":6.1,"Asian":5.5,"Hispanic_Latino":0.0},"smoking_history":{"former_current_smokers":53.0,"never_smokers":47.0}}

Statistical Information

Confidence Interval

{"rwPFS_first_line":"5.5 (4.8, 6.2)","rwOS_first_line":"13.2 (10.6, 18.4)","rwOS_second_line":"8.2 (6.6, 13.2)"}

Digital Object Identifier (DOI)

10.1002/cam4.70272

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication